XML 50 R29.htm IDEA: XBRL DOCUMENT
v3.25.0.1

SEGMENT PERFORMANCE MEASURES AND EXPENSES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES AND CONSOLIDATED NET LOSS | The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands): SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES AND CONSOLIDATED NET LOSS
|  | For the year ended December 31, |
|  | (In thousands) |  |  | Change Increase (Decrease) |
|  | 2024 |  |  | 2023 |  |  |  |  |  |  |
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Research |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OVATION |  | $ | 1,386 |  |  | $ | 1,197 |  |  | $ | 189 |  |  |  | 15.8 | %
Vaccine |  |  | 1,420 |  |  |  | - |  |  |  | 1,420 |  |  |  | 100.0 | %
Other clinical and regulatory |  |  | 2,434 |  |  |  | 1,793 |  |  |  | 641 |  |  |  | 35.8 | %
Subtotal |  |  | 5,240 |  |  |  | 2,990 |  |  |  | 2,250 |  |  |  | 75.3 | %
Non-Clinical R&D and CMC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
OVATION |  |  | 1,819 |  |  |  | 1,504 |  |  |  | 315 |  |  |  | 20.9 | %
PlaCCine Vaccine |  |  | 2,554 |  |  |  | 4,511 |  |  |  | (1,957 | ) |  |  | (43.4 | )%
Manufacturing (CMC) |  |  | 2,026 |  |  |  | 2,283 |  |  |  | (257 | ) |  |  | (11.3 | )%
Subtotal |  |  | 6,399 |  |  |  | 8,298 |  |  |  | (1,899 | ) |  |  | (22.9 | )%
Research and development expenses |  |  | 11,639 |  |  |  | 11,288 |  |  |  | 351 |  |  |  | 3.1 | %
General and administrative expenses |  |  | 7,493 |  |  |  | 9,742 |  |  |  | (2,249 | ) |  |  | (23.1 | )%
Total operating expenses |  |  | 19,132 |  |  |  | 21,030 |  |  |  | (1,898 | ) |  |  | (9.0 | )%
Loss from operations |  | $ | (19,132 | ) |  | $ | (21,030 | ) |  | $ | (1,898 | ) |  |  | (9.0 | )%

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration